Mycosis fungoides
View article: Figure S2 from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Figure S2 from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas Open
Pre- and on-treatment images of injected lesions from patients with a confirmed or unconfirmed response
View article: Figure S1 from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Figure S1 from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas Open
Time on MIW815 treatment according to dose level and indication
View article: Figure S4 from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Figure S4 from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas Open
On-treatment changes in NK-cell lineage markers in injected and noninjected lesions
View article: Supplementary Data from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Supplementary Data from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas Open
Supplementary tables and figure legends
View article: Figure S5 from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Figure S5 from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas Open
T-cell clonal expansion at Cycle 1, Day 8 and Cycle 2, Day 1 relative to pre-treatment, by patient
View article: Chlormethine gel effectiveness as second-line treatment in mycosis fungoides: a single-centre retrospective study
Chlormethine gel effectiveness as second-line treatment in mycosis fungoides: a single-centre retrospective study Open
View article: Figure S3 from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Figure S3 from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas Open
Immunohistochemistry of injected and noninjected lesions
View article: Figure S5 from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Figure S5 from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas Open
T-cell clonal expansion at Cycle 1, Day 8 and Cycle 2, Day 1 relative to pre-treatment, by patient
View article: Figure S4 from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Figure S4 from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas Open
On-treatment changes in NK-cell lineage markers in injected and noninjected lesions
View article: Figure S1 from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Figure S1 from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas Open
Time on MIW815 treatment according to dose level and indication
View article: Figure S3 from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Figure S3 from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas Open
Immunohistochemistry of injected and noninjected lesions
View article: Supplementary Data from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Supplementary Data from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas Open
Supplementary tables and figure legends
View article: Figure S2 from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Figure S2 from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas Open
Pre- and on-treatment images of injected lesions from patients with a confirmed or unconfirmed response
View article: 396 Spatially dissecting the role of macrophages in cutaneous lymphoma
396 Spatially dissecting the role of macrophages in cutaneous lymphoma Open
View article: Extracorporeal Photopheresis for the Inpatient Dermatologist
Extracorporeal Photopheresis for the Inpatient Dermatologist Open
Purpose of Review Extracorporeal photopheresis (ECP) is an immunomodulatory treatment in which an apheresis machine isolates mononuclear cells from whole blood that are then treated with psoralen and ultraviolet-A light and reinfused into …
View article: Comparative Profiling of TCR Repertoires in Extranodal NK/T-Cell Lymphoma and Healthy Individuals Highlights Unique Clonal Expansions and Potential Diagnostic Biomarkers
Comparative Profiling of TCR Repertoires in Extranodal NK/T-Cell Lymphoma and Healthy Individuals Highlights Unique Clonal Expansions and Potential Diagnostic Biomarkers Open
T-cell receptor (TCR) repertoire profiling is crucial for elucidating immune responses in Extranodal NK/T-cell lymphoma (ENKTL). In this study, TCR sequencing of paraffin-embedded samples was performed using MiXCR with stringent quality co…
View article: Mosaicism of BRAF(V600E) in Healthy Skin Predicts Neurodegeneration in Histiocytosis
Mosaicism of BRAF(V600E) in Healthy Skin Predicts Neurodegeneration in Histiocytosis Open
Most histiocytoses harbor an oncogenic somatic alteration activating the MAP kinase pathway, the most frequent of which is BRAF V600E . Targeted therapy with BRAF or MEK inhibitors is highly effective, but neurodegeneration remains a sever…
View article: Anaplastic large cell lymphoma in the penis: a case report and review of literature
Anaplastic large cell lymphoma in the penis: a case report and review of literature Open
Background Anaplastic large cell lymphoma is a distinct subtype of mature T cell lymphoma characterized by strong CD30 expression. While primary penile lymphomas are rare, they are most commonly of B cell origin, making primary T cell lymp…
View article: LAIR1 prevents excess inflammatory tissue damage in Staphylococcus aureus skin infection and Cutaneous T-cell Lymphoma
LAIR1 prevents excess inflammatory tissue damage in Staphylococcus aureus skin infection and Cutaneous T-cell Lymphoma Open
Patients with cutaneous T cell lymphoma (CTCL) experience high morbidity and mortality due to S. aureus skin infections and sepsis, but the underlying mechanisms remain unclear. We have previously identified high levels of LAIR2, a decoy p…
View article: Mycosis fongoïde avec angiotropisme : une étude rétrospective monocentrique de 10 cas
Mycosis fongoïde avec angiotropisme : une étude rétrospective monocentrique de 10 cas Open
View article: Longitudinal multimodal characterization of radiation dermatitis in the C57BL/6J mouse model
Longitudinal multimodal characterization of radiation dermatitis in the C57BL/6J mouse model Open
Radiation dermatitis (RD) is a frequent and therapy-limiting toxicity of cancer radiotherapy, yet its mechanistic basis remains poorly understood. To address the need for quantitative, mechanistic insight, we developed a longitudinal C57BL…
View article: Correction: Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma
Correction: Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma Open
View article: Computational workflow for CTCL multi-omics study
Computational workflow for CTCL multi-omics study Open
Cutaneous T-cell lymphoma (CTCL) remains a challenging disease due to its significant heterogeneity, therapy resistance, and relentless progression. Multi-omics technologies offer the potential to provide uniquely precise views of disease …
View article: Unveiling CMV-induced immune alterations in Mycosis Fungoides/Sezary syndrome patients 2508
Unveiling CMV-induced immune alterations in Mycosis Fungoides/Sezary syndrome patients 2508 Open
Description Increasing evidence suggests that Cytomegalovirus (CMV) latency induces oncomodulation, which could influence the tumor-specific immune response, and potentially the clinical outcome. Our aim was to evaluate the impact of CMV l…
View article: 192 Spatial profiling of CD8+ T cells and macrophages in the skin of patients with mycosis fungoides
192 Spatial profiling of CD8+ T cells and macrophages in the skin of patients with mycosis fungoides Open
View article: 26 eIF4E: A New Diagnostic Tool for Mycosis Fungoides
26 eIF4E: A New Diagnostic Tool for Mycosis Fungoides Open
View article: Cardiac Infiltration in Mycosis Fungoides Resulting in Recurrent Tamponade
Cardiac Infiltration in Mycosis Fungoides Resulting in Recurrent Tamponade Open
Pericardial or myocardial infiltration should be considered in patients with MF presenting with cardiac symptoms, conduction disturbance, or shock.
View article: 333 Inverse Psoriasis-Like Mogamulizumab-Associated Rash in a Patient with Cutaneous T-cell Lymphoma
333 Inverse Psoriasis-Like Mogamulizumab-Associated Rash in a Patient with Cutaneous T-cell Lymphoma Open
View article: 369 Stratum corneum ceramide profile as biomarker in cutaneous T-cell lymphoma
369 Stratum corneum ceramide profile as biomarker in cutaneous T-cell lymphoma Open
View article: 329 Serum Proteomic Analysis Distinguishes Early Mycosis Fungoides from Atopic Dermatitis
329 Serum Proteomic Analysis Distinguishes Early Mycosis Fungoides from Atopic Dermatitis Open